
Opinion|Videos|December 19, 2025
Economic Burden and Systemwide Strategies
Panelists discuss how the economic toll of poor LDL-C control demands workplace and systemwide prevention strategies.
Advertisement
Episodes in this series

Panelists discuss how poor low-density lipoprotein cholesterol (LDL-C) control imposes substantial economic costs through hospitalizations, lost productivity, and long-term treatment of cardiovascular events.
They highlight that preventive strategies—such as workplace screenings and wellness incentives—can improve early detection and reduce downstream costs.
Panelists conclude that systemwide coordination between employers, payers, and clinicians is necessary to make cholesterol control a sustainable public health priority.
Advertisement
Related to this article

Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.

These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.

Admilparant 60 mg met the ALOFT-IPF primary end point, significantly improving FVC change vs placebo at 52 weeks in idiopathic pulmonary fibrosis.

At a roundtable in Cleveland, kidney experts said IgA nephropathy and FSGS often go unrecognized, calling for EHR flags and better referral channels.

AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.

The conference session featured updates on several clinical trials, including the BRUNELLO trial, for treatment of diabetic macular edema (DME).

Panelists engaged in a debate regarding using complement inhibitors in geographic atrophy, gauging public sentiment with a deciding vote.
Advertisement
Advertisement
Trending on AJMC
1
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
2
CMS Rule Ends Medicaid, CHIP Funding for Pediatric Gender Care
3
MedHaul Closes Care Gaps With Single Stop for Getting Patients to Appointments
4
FDA Approves First Treatment for BCG-Unresponsive Bladder Cancer
5

